Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2020 | Update on the efficacy and safety of the LIBRETTO-531 trial

Mimi Hu • 21 Sep 2020
ESMO 2020
Thyroid Cancer Cabozantinib Selpercatinib Vandetanib
LIBRETTO-531

Mimi Hu, MD University of Texas MD Anderson Cancer Center, Houston, Texas, discusses the results from the LIBERTTO-531 trial (NCT04211337). This study investigated the efficacy and safety of selpercatinib compared to a standard treatment in patients with rearranged during transfection (RET)- mutant medullary thyroid cancer (MCT) that is ineligible for surgery or metastatic. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Mimi Hu

4:13
ARROW: an update on the registrational study
Mimi Hu • 21 Sep 2020
1:26
Thyroid cancer at ESMO 2020
Mimi Hu • 21 Sep 2020

Related Videos

3:19
Future directions of targeted agents in the treatment of thyroid and neuroendocrine tumors
Enrique Grande • 22 Oct 2023
3:42
AI analysis of TILs in H&E slides to explore immune phenotypes in papillary thyroid cancer
Young Kwang Chae • 4 Jun 2023
2:10
Exploring the new frontier: radionuclide therapy in metastatic prostate cancer
Jeremie Calais • 3 Jun 2023
1:17
Evaluating the genomic landscape of thyroid cancer
Blessie Elizabeth Nelson • 17 Apr 2023
The content of VJOncology is intended for healthcare professionals